Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Meningococcal Conjugate · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| MenACWY Plain Polysaccharide (ACWY Vax) | ACTIVE_COMPARATOR | The MenACWY Plain Polysaccharide Vaccine, which is already licensed and is used as a travel vaccine, is known as the MenACWY plain polysaccharide (ACWY Vax). Participants in this arm will receive 1 dose of the MenACWY plain polysaccharide (ACWY Vax) and 1 dose of the MenACWY conjugate (MenACWY). |
| MenACWY conjugate | ACTIVE_COMPARATOR | The MenACWY conjugate vaccine was licensed in the UK in March 2010, and is known as the MenACWY conjugate vaccine (Menveo). Participants in this arm will receive 2 doses of the MenACWY conjugate vaccine. |
| Name | Type | Description |
|---|---|---|
| Meningococcal (Groups A, C, Y and W-135) Conjugate | BIOLOGICAL | 2 x 0.5 mL dose |
| Meningococcal polysaccharide A, C, Y and W135 and Menveo | BIOLOGICAL | 1 x 0.5 mL dose of ACWY Vax, 1 x 0.5 mL dose of Menveo |
Inclusion Criteria: * Participant is willing and able to give informed consent for participation after the nature of the study has been explained * Male or Female, aged 18- 70 years inclusive * In good health as determined by: * Medical history * History-directed physical examination * Clini...
Meningococcal Conjugate is an investigational vaccine being developed for meningitis, a serious infection of the membranes surrounding the brain and spinal cord. It is also being studied in the context of septicemia, a related bloodstream infection. The drug is currently in Phase 3 clinical development.
Meningococcal Conjugate is being developed by Novartis AG, a global healthcare company traded on the New York Stock Exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate the vaccine's safety and immune response in adults.
Meningococcal Conjugate is currently in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. One Phase 3 trial has been completed, and the drug remains under evaluation for the prevention of meningitis.
Meningococcal Conjugate has one completed Phase 3 clinical trial registered as NCT00901940, titled 'Understanding the Immune Response to Meningitis Vaccines.' This trial enrolled 150 healthy adult volunteers in the United Kingdom and was actively controlled, meaning it compared the vaccine against an existing treatment.
Meningococcal Conjugate is a monoclonal antibody designed to target components of the bacteria that cause meningitis. By binding to specific bacterial targets, it helps the immune system recognize and fight the infection. This mechanism is intended to provide protection against meningococcal disease.